Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Resverlogix Corp (RVXCF)

Resverlogix Corp (RVXCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024 Newsfile - Tue Sep 3, 9:18AM CDT

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension Newsfile - Wed Jul 31, 5:46PM CDT

Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary,...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges Newsfile - Tue Jul 16, 6:17AM CDT

Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Updated Annual and Special Meeting of Shareholders Newsfile - Tue May 28, 4:16PM CDT

Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges Newsfile - Mon May 13, 4:12PM CDT

Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Change to Its Board of Directors Newsfile - Wed Feb 21, 6:02PM CST

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits Newsfile - Thu Jan 11, 6:20AM CST

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy Newsfile - Wed Oct 4, 2023

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage,...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes Newsfile - Tue Aug 29, 2023

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society...

RVXCF : 0.0400 (-5.88%)
RVX.TO : 0.0500 (-9.09%)
Resverlogix Announces Warrant Repricing and One-Year Extension Newsfile - Thu Jun 29, 2023

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants")...

RVX.TO : 0.0500 (-9.09%)
RVXCF : 0.0400 (-5.88%)

Barchart Exclusives

With Gold Near Record Highs, Should You Follow Insider Buying on This Dividend Stock? Barchart - 1 hour ago
One board member is loading up on the company's stock as gold prices explore new records. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot